Glycoprotein L–deleted single-cycle rhesus cytomegalovirus vectors elicit MHC-E–restricted CD8+ T cells that protect against SIV
Authors:
Open Access
- 27 May 2025
- journal article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 214 (8) , 1969-1981
Abstract
Strain 68-1 rhesus CMV (RhCMV) vectors induce immune responses that mediate early, complete replication arrest of SIV infection in ∼60% of vaccinated rhesus macaques (RMs). This unique efficacy depends on the ability of these vectors to elicit effector memory (EM)-biased CD8+ T cells recognizing SIV peptides presented by MHC-E, rather than MHC-Ia. These efficacious responses still occurred when spread of the 68-1 vector was impaired by deletion of the viral anti-host intrinsic immunity factor phosphoprotein 71 (pp71), but efficacy was lost with a more stringent attenuation strategy based on destabilization of Rh108, the ortholog of the essential human CMV (HCMV) transcription factor UL79 that is required for late viral gene expression. Although unable to produce infectious progeny (ie single-cycle infection), Rh108-deficient vectors elicited durable, high frequency, EM-biased, SIV-specific CD8+ T-cell responses in RMs, but these responses were MHC-Ia–restricted and therefore non-efficacious. Here, we tested a different single-cycle attenuation strategy based on deletion (Δ) of the glycoprotein L (gL) that is essential for viral entry but allows for late gene expression and viral assembly. ΔgL 68-1 RhCMV/SIV vectors, grown on gL-complementing fibroblasts, were robustly immunogenic at doses above 105 PFU, generating high frequency, EM-biased, SIV-specific CD8+ T-cell responses that were also unconventionally restricted, including the MHC-E restriction associated with efficacy. Indeed, these single-cycle vectors manifested replication arrest efficacy in 70% of vaccinated RMs, further linking MHC-E restriction with efficacy, and demonstrating that 68-1 RhCMV/SIV efficacy does not require vector dissemination within the host.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (U19 AI128741, P01 AI174856)
- L.J.P. (R01 AI059457)
- Bill and Melinda Gates Foundation (OPP1107409)
- National Institutes of Health, Office of the Director (P51 OD011092)
- National Cancer Institute
- National Institutes of Health (75N91019D00024)
This publication has 42 references indexed in Scilit:
- Safety, efficacy, and immunogenicity of a replication-defective human cytomegalovirus vaccine, V160, in cytomegalovirus-seronegative women: a double-blind, randomised, placebo-controlled, phase 2b trialThe Lancet Infectious Diseases, 2023
- Programming cytomegalovirus as an HIV vaccineTrends in Immunology, 2023
- Cytomegalovirus-vaccine-induced unconventional T cell priming and control of SIV replication is conserved between primate speciesCell Host & Microbe, 2022
- Comparison of vaccination with rhesus CMV (RhCMV) soluble gB with a RhCMV replication-defective virus deleted for MHC class I immune evasion genes in a RhCMV challenge modelVaccine, 2019
- The pathogenesis of human cytomegalovirusThe Journal of Pathology, 2014
- Immune clearance of highly pathogenic SIV infectionNature, 2013
- Profound early control of highly pathogenic SIV by an effector memory T-cell vaccineNature, 2011
- Human cytomegalovirus immunity and immune evasionVirus Research, 2011
- A novel chimeric Rev, Tat, and Nef (Retanef) antigen as a component of an SIV/HIV vaccineVaccine, 2002
- Distribution of human CMV-specific memory T cells among the CD8pos. subsets defined by CD57, CD27, and CD45 isoformsEuropean Journal of Immunology, 1999